The Role of Molecular Imaging in Drug Discovery and Development

  title={The Role of Molecular Imaging in Drug Discovery and Development},
  author={R. J. Hargreaves},
  journal={Clinical Pharmacology \& Therapeutics},
  • R. Hargreaves
  • Published 1 February 2008
  • Biology, Chemistry
  • Clinical Pharmacology & Therapeutics
Molecular imaging biomarkers are playing an increasingly important role in efforts to increase the probability of success of drug candidates by helping to validate novel drug targets in support of proof‐of‐concept testing early in the drug discovery and development process. By facilitating better and faster decision‐making, molecule and mechanism–based failures can be identified and eliminated from a research portfolio early in development thereby focusing research efforts on the best drug… 
Optimizing Central Nervous System Drug Development Using Molecular Imaging
CNS imaging biomarkers have the potential to drive new medical care practices for patients in the latent phases of progressive neurodegenerative disorders by enabling the detection, preventative treatment, and tracking of disease in a paradigm shift from today's approaches.
Translational neuroimaging of the CNS: novel pathways to drug development.
A brief review of examples of the new wave of neuroimaging studies that engender useful biomarkers of disease for translational research.
Clinical Application of Molecular Features in Therapeutic Selection and Drug Development
  • R. Lu, R. Tang, Jing Huang
  • Biology, Psychology
    Statistical Methods in Biomarker and Early Clinical Development
  • 2019
This chapter focuses on a specific type of biomarkers: the ones useful for therapeutic decision and therapeutic drug development in the clinical setting, and methodologies on biomarkers evaluation for clinical utility and analytical validity.
The development of biomarkers to reduce attrition rate in drug discovery focused on oncology and central nervous system
This study is focused on the high attrition rate in discovery and development of oncology and central nervous system medicines, because the failure rate of these medicines is higher than others.
Imaging as a Tumor Biomarker in Oncology Drug Trials for Lung Cancer: The FDA Perspective
The US Food and Drug Administration is working with the pharmaceutical industry, academia, and sister stakeholders in the government, primarily through collaborative educational and research efforts, to identify how imaging can serve this function.
Translational PET imaging research
Advancing Drug Discovery and Development Using Molecular Imaging (ADDMI): an Interest Group of the World Molecular Imaging Society and an Inaugural Session on Positron Emission Tomography (PET)
The ADDMI interest group launched their efforts at the 2016 World Molecular Imaging Congress by hosting a session of invited lectures on translational positron emission tomography (PET) imaging in the central nervous system and frames the role of translational imaging biomarker strategies in the drug discovery and development process.
Imaging as a Localized Biomarker: Opportunities and Challenges
Understanding the opportunities for using imaging biomarkers as tools in drug development while recognizing the current challenges and how efforts to overcome these challenges are evolving is focused on.


Optical molecular imaging in drug discovery and clinical development
The authors focus the interest of this review on optical molecular imaging technology as well as reviewing how this technology is being integrated in various therapeutic areas, and how it has started to impact the preclinical drug discovery process.
Clinical biomarkers in drug discovery and development
Clinically useful biomarkers are required to inform regulatory and therapeutic decision making regarding candidate drugs and their indications in order to help bring new medicines to the right patients faster than they are today.
The goal of this paper is to briefly review the available imaging modalities, highlight some uses of anatomical and functional imaging and then focus on exciting advances in molecular imaging and how they will affect drug discovery and development.
Small animal imaging in drug development.
Better mechanistic understanding of disease through mapping of the human and mouse genomes enables rethinking of human infirmity, and the ability to study those animals noninvasively and quantitatively with new, high-resolution imaging devices provides the most relevant milieu in which to find and examine new therapies.
A role for fMRI in optimizing CNS drug development
Drug development today needs to balance agility, speed and risk in defining the probability of success for molecules, mechanisms and therapeutic concepts. New techniques in functional magnetic
Role of in vivo imaging of the central nervous system for developing novel drugs.
  • M. A. Rueger, L. Kracht, A. Jacobs
  • Medicine, Biology
    The quarterly journal of nuclear medicine and molecular imaging : official publication of the Italian Association of Nuclear Medicine (AIMN) [and] the International Association of Radiopharmacology (IAR), [and] Section of the Society of...
  • 2007
Various imaging technologies, such as cranial computed tomography (CT), magnetic resonance imaging (MRI) and spectroscopy (MRS), positron emission tomography and single-photon emission computed tomographic (SPECT), with respect to their current applications in non-invasive disease phenotyping and the measurement of therapeutic outcomes in neurology are reviewed.
The opportunities and challenges of developing imaging biomarkers to study lung function and disease.
  • D. Schuster
  • Biology
    American journal of respiratory and critical care medicine
  • 2007
To take full advantage of the opportunities presented by state-of-the-art imaging methods, new approaches to analytic and clinical validation must be developed in collaboration with industry, foundation, and federal funding agencies.
Molecular imaging of cardiovascular disease.
Key factors spurring the growth of molecular imaging include the application of novel ligand screening methods, emerging new chemistries for conjugation and signal amplification, and nanotechnology, which have fostered substantial growth in ligand development.
Emerging concepts in molecular MRI.